<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121034">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922271</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237ADE02</org_study_id>
    <nct_id>NCT01922271</nct_id>
  </id_info>
  <brief_title>Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>FAST</acronym>
  <official_title>A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 μg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further figure out differences of glycopyrronium bromide
      compared to tiotropium in early bronchodilation measured by a comprehensive assessment of
      lung function that includes hyperinflation and specific airway resistance in patients with
      moderate to severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Airway Resistance (sRAW)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa*s. Whole body plethysmography (Bodybox) is used to measure SRaw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity (TLC)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Residual Capacity (FRCpleth)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional Residual Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume (RV)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium followed by NVA237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237</intervention_name>
    <description>NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium 18 μg once daily delivered via HandiHaler® device.</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to NVA237</intervention_name>
    <description>Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).</description>
    <arm_group_label>Tiotropium followed by NVA237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to tiotropium</intervention_name>
    <description>Placebo to tiotropium once daily delivered via HandiHaler® device</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Used as resuce medication</description>
    <arm_group_label>NVA237 followed by tiotropium</arm_group_label>
    <arm_group_label>Tiotropium followed by NVA237</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged ≥40 years

          -  Patients with moderate to severe COPD defined by a post-bronchodilator Forced
             Expiratory Volume in One Second (FEV1)/(FVC) Forced Vital Capacity ratio of &lt;0.70 and
             a post-bronchodilator FEV1 of  ≤70% and FEV1 ≥ 30% of predicted normal values.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Patients who have a clinically significant laboratory abnormality at run-in

          -  Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or
             bladder-neck obstruction or moderate to severe renal impairment (GFR &lt;50
             ml/min/1,732) or urinary retention. (BPH patients who are stable on treatment can be
             considered).

          -  Patients with any history of asthma

          -  Patients with pulmonary lobectomy or lung volume reduction surgery or lung
             transplantation

          -  Patients receiving medications in the classes listed in the protocol as prohibited.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12687</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22947</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gummersbach</city>
        <zip>51643</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Tiotropium</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
